GlioGuard

Executive Summary

Glioblastoma (GBM) is the most aggressive primary brain cancer, with a median survival of less than two years despite standard-of-care surgery, radiation, and temozolomide. Tumor recurrence is inevitable, and no effective therapies exist for relapsed disease. GlioGuard aims to transform this prognosis by developing a novel therapeutic approach that targets GBM's unique biology. The company's lead candidate is designed to overcome the blood-brain barrier and specifically attack tumor-initiating cells, with the goal of achieving durable responses and improving patient outcomes. Founded in 2018 and based in Milan, Italy, GlioGuard is advancing its proprietary platform toward clinical validation. The company has completed preclinical studies demonstrating efficacy in orthotopic models and is preparing for first-in-human trials. With glioblastoma representing a high unmet medical need and a sizable market, GlioGuard's approach has attracted interest from European oncology specialists. Upcoming milestones include initial clinical data and potential regulatory designations that could accelerate development and de-risk the program.

Upcoming Catalysts (preview)

• Q3 2026Phase 1/2a First-in-Human Trial Initiation75% success
• Q4 2026Orphan Drug Designation from EMA80% success
• Q2 2027Interim Safety and Efficacy Data from Phase 160% success